Gene Therapy Development for Breast Cancer

Introduction of Gene Therapy

In recent years, with the vigorous development of gene editing technology and biomedical materials science, the dawn of gene therapy has arrived. Thanks to great advances in gene editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR) and gene editing technology, gene therapy can be delivered in a more convenient and precise manner. The concept of gene therapy was developed based on the theory that correcting cancer-related mutations can control or inhibit the growth of cancer cells and improve patient prognosis. Gene delivery systems, including viral and non-viral vectors, also determine their clinical safety and efficiency. Breast cancer (BC) is one of the most lethal cancers in women, and using DNA- or RNA-based gene therapy has the potential to address key candidate genes in BC.

Fig. 1. Cancer gene therapy with the delivery of tumor-suppressor genes (TSGs) or inhibition of oncogene expression. (Dastjerd NT, et al, 2022)

Breast Cancer Gene Therapy Development Services

Gene therapy development is a young field facing a wide range of challenges, including a dynamic regulatory environment, pre-existing and treatment-induced immunity to viral vectors. Alfa Cytology's preclinical gene therapy development services ensure the comprehensive services and expertise needed to create solutions for every gene therapy development challenge, from IND-enabled testing to commercialization, ready to advance your development program.

Biomarker assays are critical for the development of gene therapies, particularly for the assessment of T and B cell immunogenicity. Alfa Cytology has industry-leading expertise in biomarker and immunogenicity assays and is at the forefront of immunogenicity testing for gene therapy trials. Services we can provide include:

• Immunogenicity testing
  • Cell-based NAB assay
  • PK/PD testing
  • Learn more about our professional laboratory services
• Preclinical gene therapy safety testing
  • Viral biodistribution by ddPCR, qPCR (mouse/NHP or other species required)
  • Assess the accuracy and specificity of gene editing by NGS (mouse/NHP, or other species as desired)
  • DNA/RNA extraction via automated system

Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC gene therapy development services and help in the development of therapies and diagnostics for BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.